Open AccessInclisiran (Leqvio)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.312
Subject(s) - reimbursement , medicine , familial hypercholesterolemia , drug , drug class , statin , ldl cholesterol , physical therapy , intensive care medicine , cholesterol , pharmacology , political science , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses inclisiran (Leqvio), 284 mg in 1.5 mL (189 mg/mL) solution for SC injection.
Indication: As an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) level in adults with the following conditions who are on a maximally tolerated dose of a statin, with or without other LDL-C-lowering therapies:
heterozygous familial hypercholesterolemia (HeFH), or
non-familial hypercholesterolemia with atherosclerotic cardiovascular disease.